DNA test

23andM3 executive ring the Nasdaq opening bell on the day the company goes public

23andMe snags 3rd FDA nod for genetic cancer risk test

23andMe’s analysis can connect long-lost relatives, teach them about how DNA influences their lives and, now, determine their risk of prostate cancer.

Andrea Park Jan 10, 2022 11:58am

Helix doubles down on COVID-19 surveillance with $50M series C

Jun 4, 2021 11:29am

23andMe to shut off third-party access to its genome API: CNBC

Aug 24, 2018 1:20pm

Diassess to get up to $21.9M to develop at-home flu diagnostic

Jul 17, 2018 3:56pm

Helix raises $200M series B for DNA test marketplace

Mar 8, 2018 8:26am

Helix debuts online marketplace for personal genomics products

Jul 24, 2017 11:16am